New cancer drug YL217 enters first human tests for advanced tumors
NCT ID NCT06859762
First seen Nov 03, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This early-phase study tests a new drug, YL217, in about 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also seeing if the drug can shrink tumors. Participants must be in good overall health (ECOG 0 or 1) and have adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
Contact
-
Cleveland Clinic Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
-
Duke University Medical Center (DUMC)
RECRUITINGDurham, North Carolina, 27710, United States
Contact
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
Contact
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Bejing, 100730, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
The University of Kansas Cancer Center (KUCC)
RECRUITINGKansas City, Kansas, 66205, United States
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
-
UCLA Hematology/Oncology - Santa Monica
RECRUITINGSanta Monica, California, 90404, United States
Contact
-
UT Health San Antonio - Mays Cancer Center
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
University of Cincinnati Medical Center
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
-
University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
Contact
-
University of Wisconsin Health - UW Carbone Cancer Center
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06519, United States
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.